Comparison of methods to detect the in vitro activity of silver nanoparticles (AgNP) against multidrug resistant bacteria by Cavassin, Emerson Danguy et al.
  Universidade de São Paulo
 
2015
 
Comparison of methods to detect the in vitro
activity of silver nanoparticles (AgNP) against
multidrug resistant bacteria
 
 
Journal of Nanobiotechnology. 2015 Oct 05;13(1):64
http://www.producao.usp.br/handle/BDPI/49153
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Moléstias Infecciosas e Parasitárias - FM/MIP Artigos e Materiais de Revistas Científicas - FM/MCG
Cavassin et al. J Nanobiotechnol  (2015) 13:64 
DOI 10.1186/s12951-015-0120-6
RESEARCH
Comparison of methods to detect the 
in vitro activity of silver nanoparticles (AgNP) 
against multidrug resistant bacteria
Emerson Danguy Cavassin1, Luiz Francisco Poli de Figueiredo2, José Pinhata Otoch2, Marcelo Martins Seckler3, 
Roberto Angelo de Oliveira3, Fabiane Fantinelli Franco4, Valeria Spolon Marangoni4, Valtencir Zucolotto4, 
Anna Sara Shafferman Levin1 and Silvia Figueiredo Costa1,5*
Abstract 
Background: Multidrug resistant microorganisms are a growing challenge and new substances that can be useful to 
treat infections due to these microorganisms are needed. Silver nanoparticle may be a future option for treatment of 
these infections, however, the methods described in vitro to evaluate the inhibitory effect are controversial.
Results: This study evaluated the in vitro activity of silver nanoparticles against 36 susceptible and 54 multidrug 
resistant Gram-positive and Gram-negative bacteria from clinical sources. The multidrug resistant bacteria were oxa-
cilin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus spp., carbapenem- and polymyxin B-resistant 
A. baumannii, carbapenem-resistant P. aeruginosa and carbapenem-resistant Enterobacteriaceae. We analyzed silver 
nanoparticles stabilized with citrate, chitosan and polyvinyl alcohol and commercial silver nanoparticle. Silver sulfadia-
zine and silver nitrate were used as control. Different methods were used: agar diffusion, minimum inhibitory concen-
tration, minimum bactericidal concentration and time-kill. The activity of AgNPs using diffusion in solid media and the 
MIC methods showed similar effect against MDR and antimicrobial-susceptible isolates, with a higher effect against 
Gram-negative isolates. The better results were achieved with citrate and chitosan silver nanoparticle, both with MIC90 
of 6.75 μg mL−1, which can be due the lower stability of these particles and, consequently, release of Ag+ ions as 
revealed by X-ray diffraction (XRD). The bactericidal effect was higher against antimicrobial-susceptible bacteria.
Conclusion: It seems that agar diffusion method can be used as screening test, minimum inhibitory concentration/
minimum bactericidal concentration and time kill showed to be useful methods. The activity of commercial silver 
nanoparticle and silver controls did not exceed the activity of the citrate and chitosan silver nanoparticles. The in vitro 
inhibitory effect was stronger against Gram-negative than Gram-positive, and similar against multidrug resistant and 
susceptible bacteria, with best result achieved using citrate and chitosan silver nanoparticles. The bactericidal effect of 
silver nanoparticle may, in the future, be translated into important therapeutic and clinical options, especially consid-
ering the shortage of new antimicrobials against the emerging antimicrobial resistant microorganisms, in particular 
against Gram-negative bacteria.
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Background
In the last decade, the emergence of multidrug-resistant 
bacteria (MDR) became a challenge around the world [1]. 
Antimicrobial resistance is recognized as a medical prob-
lem that increases mortality, morbidity rates, length of 
stay and cost and has nowadays few therapeutic possibili-
ties [2]. In this scenario, new products such as nanotech-
nology may have a role to treat infections due to MDR 
[3].
Nanotechnology is opening possibilities, allowing new 
solutions with old resources. Nanoscale materials such 
as silver nanoparticles (AgNPs) have emerged as novel 
agents because their high surfaces area to volume ratio 
and the unique chemical and physical properties [4]. Sil-
ver nanoparticles have greater efficiency in mediating 
their antimicrobial activity when compared with silver 
salts [5, 6]. Because AgNPs acts synergistically in distinct 
targets it is expected that there will be no interference 
with antimicrobial resistance mechanisms. Thus, AgNPs 
has a potential use to treat MDR.
However, the mechanisms by which AgNPs act against 
bacteria are not yet fully elucidated. It is believed that in 
aqueous solution biologically active Ag+ ions are deliv-
ered and promotes the antimicrobial effect [5–7]. Sil-
ver nanoparticles interact with three vital components 
of the cells: (a) peptidoglycan cell wall, (b) cytoplasmic 
membrane, where chemical and physical properties are 
modified and results in an imbalance of osmolality, per-
meability, electron transport, and cellular breathing and 
(c) ribosomal DNA, molecular sites of phosphorus and 
sulfur present in proteins, especially in enzymes involved 
in the electron transport chain [7].
Currently there is a recommendation by International 
Organization for Standardization (ISO), a worldwide 
federation of national standards [8, 9], for evaluating 
potency of silver nanoparticles against cell wall degrada-
tion of Staphylococcus aureus and muramic acid release, 
using gas chromatography-mass spectrometry (GC-MS) 
[8, 10].
However, studies in the literature have used the meth-
ods recommended for antimicrobial drugs: diffusion in 
agar and determination of minimum inhibitory concen-
tration (MIC) [11–13] and minimum bactericidal con-
centration (MBC) according to the current Clinical and 
Laboratory Standards Institute (CLSI) document recom-
mendation [14].
The aim of this study was to evaluate the in vitro activ-
ity of AgNPs stabilized with different compounds against 
MDR and antimicrobial-susceptible Gram-positive and 
Gram-negative microorganisms, using different methods.
Results and discussion
AgNPs
The size and morphology of the AgNPs were investigated 
by Field Emission Gun Scanning Electron Microscope–
FEG-SEM (Fig.  1). PVA-AgNPs and Chitosan-AgNPs 
presented an average diameter around 10 and 25  nm, 
respectively, while the citrate-AgNPs have around 40 nm 
of diameter. The UV–VIS spectra in Fig. 2 show the opti-
cal properties of PVA, Chitosan and Citrate stabilized 
AgNPs. The results reveal the surface plasmon reso-
nances peaks around 400  nm for all systems, which is 
typical for nanostructured silver [15–17]. It is well known 
that the surface plasmon resonances depend strongly on 
the size, shape and functionalization of the metallic NPs 
[18]. The increasing in the size of the AgNPs leads to a 
red-shift and broadening of the plasmon resonance band 
[18], which agree with the spectrum observed for Citrate-
AgNPs. The zeta potential analysis reveals significant dif-
ferences in the surface charges between the three systems 
(Table 1). Chitosan AgNPs presented high positively sur-
face charge (+41.1 mV), while the citrate ones were very 
negative (−48.4 mV) and PVA AgNPs were more close to 
zero (−17.0 mV).
Figure  3 shows the x-ray diffraction spectra of the 
AgNPs stabilized by PVA, chitosan and citrate. The spec-
tra of PVA AgNP and chitosan AgNP reveals the exist-
ence of the peaks at 2θ = 38.15°, 44.34°, 64.5° and 77.46°, 
Fig. 1 FEG-SEM micrographs of AgNPs stabilized by a PVA, b chitosan and c citrate
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which can be assigned to the (111), (200), (220), and (311) 
reflections of the face centered cubic (fcc) structure of 
metallic silver, respectively [19–21]. No impurities were 
detected in the XRD profile of AgNPs-PVA. However, 
some intense peaks at 2θ angles of 32.2°, 46.3°, 54.7° 
and 57.3° were observed in the XRD profile of AgNPs-
chitosan. Several studies attribute the presence of these 
small additional peaks to the crystalline organic phase 
[22, 23]. On the other side, the peaks at 32.2° and 54.7° 
also match with the diffraction profile of the Ag2O [24, 
25] and might be an indicate that some silver oxide have 
been formed during the synthesis or the drying process 
of AgNPs in presence of chitosan.
The spectrum of citrate AgNPs shows no peak associate 
to metallic nanoparticle. The peak around 32° can be can 
be assigned to silver salt. Since we observed the forma-
tion of the silver nanoparticles in all our previous charac-
terizations such as FEG-SEM and UV–VIS spectroscopy, 
this finding suggests that the metallic silver were oxidized 
to ions during the drying process and implies that the 
sodium citrate is not a good stabilizer to protect the silver 
particles against oxidation.
The diameter of the particles (d) stabilized with PVA 
and chitosan were estimated by Scherrer equation (Eq. 1), 
where 0.94 is the constant value used for spherical par-
ticle shape, λ is the X-ray wavelength (0.15406  nm), B 
is the line broadening at half maximum intensity of the 
selected reflection plane in radians, and θ is the Bragg 
angle.
The mean crystalline particles size were determined 
from the main (111) diffraction peak (2θ = 38.15°) of the 
X-ray diffraction pattern. The diameter found for PVA 
was 7.1 nm, which is close to the diameter found by SEM 
images. However, the calculated diameter for chitosan-
AgNPs were around 11.9  nm, while the one obtained 
from the SEM images were 25 nm. This difference might 
be related to the oxidation of silver ions during the drying 
process, which was showed in the X-ray pattern, and con-
sequently decrease in the nanoparticle size.
Growth inhibition by diffusion
All inhibition zones produced were plotted according to 
their size (Fig. 4). The inhibition zone was similar com-
paring MDR and susceptible bacteria, with larger zones 
for citrate and chitosan AgNPs than PVA AgNPs. Sil-
ver nitrate had no activity against MDR by this method 
(Fig. 5).
(1)d =
0.94
B cos θ
300 400 500 600 700
0.0
0.2
0.4
0.6
0.8
1.0  AgNP - chitosan
 AgNP- PVA
 AgNP - citrate
A
bs
or
ba
nc
e
Wavelength / nm
Fig. 2 UV-vis spectroscopy spectra of PVA, chitosan and citrate 
AgNPs
Table 1 Zeta potential for PVA, chitosan and citrate AgNPs
AgNPs Potential zeta
AgNP–PVA −17.0 mV
AgNP–Chitosan +41.1 mV
AgNP–Citrate −48.4 mV
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Fig. 3 X-ray diffraction patterns for AgNPs stabilized by a PVA, b chitosan and c citrate
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Determination of minimum inhibitory concentration (MIC)
The analysis of MIC90 results were grouped in MDR and 
susceptible isolates (Table  2), the results against Gram-
positive and Gram-negative were similar for chitosan 
AgNPs (6.75 μg mL−1), PVA AgNPs (≥54 μg mL−1) and 
commercial AgNPs (≥10  μg  mL−1). The MIC90 for cit-
rate AgNPs was higher against susceptible Gram-positive 
isolates (13.5  μg  mL−1) than against susceptible Gram-
negative and MDR (6.75 μg mL−1). Regarding the silver 
controls, Ag sulfadiazine and Ag nitrate, the MIC90 were 
respectively ≥27 and 13.5  μg  mL−1, for Gram-positive 
isolates and 13.5 and 6.75  μg  mL−1 for Gram-negative, 
independent of its antimicrobial resistance profile. In all 
tests the control silver sulfadiazine showed higher MIC90 
results than citrate and chitosan AgNPs, while silver 
nitrate showed similar results to citrate AgNPs, except 
for a lower inhibitory effect against MDR Gram-positive 
(13.5  μg  mL−1). It was not possible to define the exact 
MIC90 values for commercial AgNPs (≥10 μg mL−1) and 
PVA AgNPs, the less potent AgNPs particle evaluated 
was ≥54  μg  mL−1 (Fig.  6). Summarizing, the effect of 
AgNPs was similar regardless of antimicrobial resistance 
profile and showed better activity against Gram-negative.
Determination of minimum bactericidal concentration 
(MBC)
Citrate AgNPs and chitosan AgNPs had higher bacteri-
cidal effect than PVA AgNPs and all controls. Both cit-
rate and chitosan achieved bactericidal effect over 97  % 
of antimicrobial-susceptible bacteria and 93 and 94  % 
respectively for MDR. For controls, silver nitrate was 
bactericidal over 83  % of both MDR and antimicrobial-
susceptible bacteria while silver sulfadiazine was 61 
and 67  % respectively (Fig.  7). Citrate AgNPs were bac-
teriostatic against three A. baumannii MDR isolates, 
with MBC/MIC ≥8 [26]. The results showed higher 
bactericidal effect against antimicrobial-susceptible bac-
teria than against MDR (Table 2).
Time‑kill
The most significant reduction in the number of cfu 
in the shortest period of time occurred using chitosan 
AgNPs against the MSSA isolate (4 dilutions) and MRSA 
isolate (3 dilutions). After 12 h the MDR microorganism 
decreased its multiplication reaching the initial number 
of cfu, while the multiplication of antimicrobial-suscepti-
ble isolates remained until the end of 24 h, the low counts 
was reached after the 6th hour (Fig.  8). Among Gram-
negative the greatest reduction was observed for chitosan 
AgNPs against MDR-K. pneumoniae (4 dilutions) and 
against the antimicrobial-susceptible isolate of E. aero-
genes (4 dilutions). Both remained at 101 cfu mL−1 at the 
end of 24 h (Fig. 9).
As expected, the growth of the microorganisms tested 
in sub-inhibitory concentrations showed similar behavior 
when compared to positive controls, without AgNPs. The 
curves also showed the inhibitory effect of blood on the 
activity of all silver compounds and controls.
The present study evaluated the in  vitro activity of 
three AgNPs stabilized with different compounds, 
against clinical isolates including MDR bacteria. The 
activity of AgNPs using diffusion in solid media and the 
MIC methods showed similar effect against MDR and 
antimicrobial-susceptible isolates, with a higher effect 
against Gram-negative isolates. The best inhibitory effect 
was achieved with citrate and chitosan AgNPs against 
Gram-negative bacteria.
The AgNPs showed a good in  vitro activity against 
Gram-negative with different mechanism of resistance, 
including Enterobacteria harboring carbapenemase 
(KPC), Acinetobacter harboring oxacilinases, and P. aer-
uginosa harboring metallo-beta-lactamases. Interesting 
Fig. 4 Inhibition by diffusion in depth with AgNPs particles synthesized by IFSC-USP (citrate, chitosan and PVA AgNPs), for P. aeruginosa INCQS 230 
in agar MHA (left) and the same microorganism in MHA blood 5 % (right)
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Fig. 5 Distribution of size of inhibition zones (mm) obtained by diffusion in depth with AgNPs (citrate, chitosan and PVA) and controls against 
multidrug-resistant (MDR) (n = 54) and antimicrobial-susceptible bacteria (n = 36). Asterisk Only inhibition zones >6 mm were presented. All silver 
compounds showed absence of inhibition zones (<6 mm) when tested in MHA 5 % blood against the same microorganisms
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Table 2 MIC, MIC50, MIC90 and MBC for MDR (n = 56) and antimicrobial susceptible microorganisms (n = 34)
Microorganism Citrate Chitosan PVA Ag Sulfadiazin Ag Nitrate Commercial 
AgNPs
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
A. baumannii MDR (A1) 3.4 13.5 6.7 6.7 ≥54 ≥54 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A2) 3.4 3.4 6.7 6.7 27 27 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A3) 3.4 13.5 6.7 6.7 13.5 13.5 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A4) 3.4 13.5 6.7 6.7 ≥54 ≥54 13.5 13.5 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A5) 3.4 13.5 6.7 6.7 13.5 13.5 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A6) 3.4 13.5 6.7 6.7 13.5 13.5 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A7) 3.4 27 6.7 6.7 13.5 27 6.7 13.5 3.4 13.5 ≥10 ≥10
A. baumannii MDR (A8) 3.4 27 6.7 27 13.5 13.5 6.7 13.5 3.4 13.5 ≥10 ≥10
A. baumannii MDR (A9) 3.4 27 6.7 6.7 13.5 13.5 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A10) 3.4 3.4 6.7 6.7 13.5 13.5 13.5 13.5 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A11) 3.4 13.5 6.7 6.7 13.5 27 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii MDR (A12) 3.4 3.4 6.7 6.7 27 27 13.5 13.5 3.4 3.4 ≥10 ≥10
MIC50 A. baumannii MDR 3.4 – 6.7 – 13.5 – 6.7 – 3.4 – ≥10 –
MIC90 A. baumannii MDR 3.4 – 6.7 – ≥54 – 13.5 – 3.4 – ≥10 –
A. baumannii S (AS1) 3.4 3.4 3.4 6.7 6.7 13.5 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii S (AS2) 1.6 3.4 1.6 1.6 6.7 13.5 6.7 13.5 3.4 3.4 ≥10 ≥10
A. baumannii S (AS3) 3.4 3.4 3.4 3.4 6.7 13.5 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii S (AS4) 3.4 3.4 3.4 3.4 27 27 6.7 6.7 3.4 3.4 ≥10 ≥10
A. baumannii S (AS5) 3.4 3.4 3.4 6.7 ≥54 ≥54 6.7 6.7 3.4 3.4 ≥10 ≥10
MIC50 A. baumannii S 3.4 – 3.4 – 6.7 – 6.7 – 3.4 – ≥10 –
MIC90 A. baumannii S 3.4 – 3.4 – ≥54 – 6.7 – 3.4 – ≥10 –
S. maltophilia MDR (MO9) 1.6 13.5 6.7 6.7 ≥54 ≥54 6.7 6.7 3.4 3.4 ≥10 ≥10
S. maltophilia MDR (MO11) 1.6 3.4 6.7 6.7 ≥54 ≥54 6.7 6.7 6.7 6.7 ≥10 ≥10
MIC50 S. maltophilia MDR 1.6 – 6.7 – ≥54 – 6.7 – 3.4 – ≥10 –
MIC90 S. maltophilia MDR 1.6 – 6.7 – ≥54 – 6.7 – 6.7 – ≥10 –
P. aeruginosa MDR (P1) 3.4 3.4 6.7 13.5 27 ≥54 6.7 6.7 1.6 1.6 ≥10 ≥10
P. aeruginosa MDR (P2) 3.4 6.7 6.7 13.5 13.5 27 13.5 13.5 3.4 6.7 ≥10 ≥10
P. aeruginosa MDR (P3) 3.4 3.4 6.7 13.5 13.5 27 13.5 13.5 3.4 3.4 ≥10 ≥10
P. aeruginosa MDR (P4) 3.4 13.5 6.7 13.5 13.5 ≥54 13.5 13.5 6.7 ≥27 ≥10 ≥10
P. aeruginosa MDR (P5) 3.4 3.4 6.7 13.5 13.5 27 6.7 6.7 3.4 6.7 ≥10 ≥10
MIC50 P. aeruginosa MDR 3.4 – 6.7 – 13.5 – 13.5 – 3.4 – ≥10 –
MIC90 P. aeruginosa MDR 3.4 – 6.7 – 27 – 13.5 – 6.7 – ≥10 –
P. aeruginosa S (PS1) 3.4 34 6.7 13.5 13.5 13.5 6.7 6.7 3.4 13.5 ≥10 ≥10
P. aeruginosa S (PS2) 3.4 3.4 6.7 6.7 13.5 ≥54 13.5 13.5 6.7 13.5 ≥10 ≥10
P. aeruginosa S (PS3) 3.4 1.6 3.4 3.4 ≥54 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
P. aeruginosa S (PS4) 1.6 1.6 3.4 6.7 13.5 13.5 3.4 13.5 1.6 3.4 ≥10 ≥10
P. aeruginosa S (PS5) 1.6 3.4 6.7 13.5 13.5 27 6.7 6.7 3.4 3.4 ≥10 ≥10
P. aeruginosa S (PS6) 1.6 3.4 6.7 13.5 6.7 ≥54 6.7 13.5 3.4 3.4 ≥10 ≥10
P. aeruginosa S (PS7) 1.6 3.4 3.4 13.5 6.7 13.5 13.5 13.5 6.7 6.7 ≥10 ≥10
P. aeruginosa ATCC 27853 S (MO18) 3.4 6.7 13.5 13.5 13.5 ≥54 6.7 6.7 3.4 3.4 ≥10 ≥10
MIC50 P. aeruginosa S 1.6 – 6.7 – 13.5 – 6.7 – 3.4 – ≥10 –
MIC90 P. aeruginosa S 3.4 – 13.5 – ≥54 – 13.5 – 6.7 – ≥10 –
Enterobacteriaceae MDR (K1) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 13.5 6.7 ≥27 ≥10 ≥10
Enterobacteriaceae MDR (K2) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae MDR (K3) 6.7 13.5 6.7 6.7 13.5 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae MDR (K4) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae MDR (K5) 6.7 6.7 6.7 6.7 27 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
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Table 2 continued
Microorganism Citrate Chitosan PVA Ag Sulfadiazin Ag Nitrate Commercial 
AgNPs
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
Enterobacteriaceae MDR (K6) 6.7 13.5 6.7 6.7 27 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae MDR (K7) 6.7 6.7 6.7 6.7 27 27 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae MDR (K9) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae MDR (K14) 6.7 27 6.7 13.5 ≥54 ≥54 13.5 13.5 6.7 ≥27 ≥10 ≥10
Enterobacteriaceae MDR (MO13) 3.3 3.3 3.3 3.3 13.5 13.5 13.5 13.5 6.7 ≥27 ≥10 ≥10
Enterobacteriaceae MDR (MO8) 3.3 13.5 6.7 6.7 ≥54 ≥54 13.5 13.5 3.4 3.4 ≥10 ≥10
Enterobacteriaceae MDR (MO10) 3.3 3.3 6.7 6.7 ≥54 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
MIC50 Enterobacteriaceae MDR 6.7 – 6.7 – ≥54 – 13.5 – 6.7 – ≥10 –
MIC90 Enterobacteriaceae MDR 6.7 – 6.7 – ≥54 – 13.5 – 6.7 – ≥10 –
Enterobacteriaceae S (ENB1) 3.4 3.4 6.7 6.7 27 27 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae S (ENB2) 6.7 6.7 3.4 6.7 ≥54 ≥54 13.5 13.5 13.5 13.5 ≥10 ≥10
Enterobacteriaceae S (ENB3) 3.4 3.4 3.4 3.4 13.5 13.5 13.5 13.5 3.4 6.7 ≥10 ≥10
Enterobacteriaceae S (ENB4) 6.7 6.7 3.4 6.7 27 27 13.5 13.5 6.7 ≥27 ≥10 ≥10
Enterobacteriaceae S (ENB5) 6.7 6.7 6.7 6.7 27 27 13.5 ≥27 6.7 6.7 ≥10 ≥10
Enterobacteriaceae S (ENB6) 6.7 6.7 6.7 6.7 27 27 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae S (ENB7) 6.7 6.7 3.4 3.4 13.5 13.5 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae S (ENB8) 3.4 3.4 3.4 3.4 13.5 27 13.5 13.5 6.7 6.7 ≥10 ≥10
Enterobacteriaceae S (ENB9) 3.4 27 3.4 3.4 ≥54 ≥54 13.5 13.5 6.7 6.7 ≥10 ≥10
MIC50 Enterobacteriaceae S 6.7 – 3.4 – 27 – 13.5 – 6.7 – ≥10 –
MIC90 Enterobacteriaceae S 6.7 – 6.7 – ≥54 – 13.5 – 13.5 – ≥10 –
S. aureus MRSA (S1) 6.7 6.7 3.4 27 ≥54 ≥54 13.5 13.5 13.5 ≥27 ≥10 ≥10
S. aureus MRSA (S2) 6.7 13.5 3.4 6.7 ≥54 ≥54 ≥27 ≥27 13.5 ≥27 ≥10 ≥10
S. aureus MRSA (S3) 6.7 13.5 3.4 3.4 ≥54 ≥54 ≥27 ≥27 13.5 ≥27 ≥10 ≥10
S. aureus MRSA (S4) 6.7 13.5 3.4 3.4 ≥54 ≥54 ≥27 ≥27 13.5 ≥27 ≥10 ≥10
S. aureus MRSA (S5) 6.7 13.5 3.4 3.4 ≥54 ≥54 13.5 13.5 13.5 13.5 ≥10 ≥10
S. aureus MRSA (S6) 6.7 13.5 3.4 27 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (S7) 6.7 13.5 3.4 3.4 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (S8) 6.7 13.5 3.4 3.4 27 27 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (MO1) 6.7 27 3.4 27 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (MO2) 6.7 13.5 3.4 3.4 ≥54 ≥54 13.5 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (MO3) 6.7 13.5 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (MO4) 6.7 13.5 6.7 27 ≥54 ≥54 ≥27 ≥27 13.5 ≥27 ≥10 ≥10
S. aureus MRSA (MO5) 6.7 13.5 6.7 27 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (MO6) 13.5 27 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MRSA (MO7) 13.5 13.5 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
MIC50 S. aureus MRSA 6.7 – 3.4 – ≥54 – ≥27 – 13.5 – ≥10 –
MIC90 S. aureus MRSA 13.5 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
S. aureus MSSA (MSSA1) 13.5 27 6.7 27 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MSSA (MSSA2) 6.7 13.5 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MSSA (MSSA3) 6.7 13.5 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MSSA (MSSA4) 6.7 13.5 6.7 ≥54 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MSSA (MSSA5) 6.7 13.5 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus MSSA (MSSA6) 6.7 13.5 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
S. aureus ATCC29213 (MO17) 13.5 27 3.4 6.7 ≥54 ≥54 ≥27 ≥27 13.5 ≥27 ≥10 ≥10
S. epidermidis INCQS198 (MO16) 6.7 6.7 6.7 6.7 27 27 6.7 13.5 6.7 6.7 ≥10 ≥10
MIC50 S. aureus MSSA 6.7 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
MIC90 S. aureus MSSA 13.5 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
Enterococcus sp. VRE (V1) 6.7 27 6.7 27 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
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points of this study were the inclusion of MDR clinical 
isolates with previously studied mechanisms of resist-
ance, paired with susceptible isolates, and the large num-
ber of isolates evaluated.
In an attempt to reduce the selection of resistant 
microorganisms, antimicrobials should have bactericidal 
effect which can be determined by the ratio MBC/MIC 
≤4 [26]. The present study showed the predominance of 
the bactericidal effect of AgNPs particles studied, similar 
to previously described [3]. The best bactericidal effect 
was achieved with citrate and chitosan AgNPs against 
susceptible bacteria. Citrate AgNPs showed the highest 
Table 2 continued
Microorganism Citrate Chitosan PVA Ag Sulfadiazin Ag Nitrate Commercial 
AgNPs
MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC MIC MBC
Enterococcus sp. VRE (V2) 6.7 27 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
Enterococcus sp. VRE (V3) 6.7 27 6.7 6.7 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
Enterococcus sp. VRE (V4) 6.7 27 6.7 13.5 ≥54 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
Enterococcus sp. VRE (V5) 6.7 27 6.7 13.5 27 ≥54 ≥27 ≥27 13.5 13.5 ≥10 ≥10
Enterococcus sp. VRE (V6) 6.7 13.5 3.4 13.5 ≥54 ≥54 ≥27 ≥27 6.7 13.5 ≥10 ≥10
Enterococcus sp. VRE (V7) 6.7 27 3.4 6.7 27 ≥54 ≥27 ≥27 6.7 13.5 ≥10 ≥10
Enterococcus sp. VRE (V8) 6.7 27 6.7 6.7 13.5 13.5 ≥27 ≥27 13.5 13.5 ≥10 ≥10
MIC50 Enterococcus sp. VRE 6.7 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
MIC90 Enterococcus sp. VRE 6.7 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
Enterococcus sp. VSE (VSE1) 6.7 27 6.7 13.5 27 ≥54 ≥27 ≥27 ≥27 ≥27 ≥10 ≥10
Enterococcus sp. VSE (VSE2) 6.7 6.7 6.7 13.5 ≥54 ≥54 13.5 ≥27 ≥27 ≥27 ≥10 ≥10
Enterococcus sp. VSE (VSE3) 13.5 13.5 3.4 3.4 ≥54 ≥54 ≥27 ≥27 ≥27 ≥27 ≥10 ≥10
Enterococcus sp. VSE (VSE4) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 13.5 13.5 13.5 ≥10 ≥10
Enterococcus sp. VSE (VSE5) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 13.5 13.5 13.5 ≥10 ≥10
Enterococcus sp. VSE (VSE6) 6.7 6.7 6.7 6.7 ≥54 ≥54 13.5 ≥27 13.5 ≥27 ≥10 ≥10
MIC50 Enterococcus sp. VSE 6.7 – 6.7 – ≥54 – 13.5 – 13.5 – ≥10 –
MIC90 Enterococcus sp. VSE 13.5 – 6.7 – ≥54 – ≥27 – ≥27 – ≥10 –
MDR (N = 54)
 MIC50 MDR 6.7 – 6.7 – ≥54 – 13.5 – 6.7 – ≥10 –
 MIC90 MDR 6.7 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
Susceptible (N = 36)
 MIC50 Susceptible 6.7 – 6.7 – ≥54 – 13.5 – 6.7 – ≥10 –
 MIC90 Susceptible 6.7 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
TOTAL (N = 90)
 MIC50 6.7 – 6.7 – ≥54 – 13.5 – 6.7 – ≥10 –
 MIC90 6.7 – 6.7 – ≥54 – ≥27 – 13.5 – ≥10 –
Fig. 6 MIC90 for AgNPs (citrate, chitosan and PVA) and controls comparing the subgroups MDR Gram-negative GN (n = 31) versus MDR Gram-
positive GP (n = 23) (totalizing n = 54) and antimicrobial-susceptible GN (n = 22) versus GP (n = 14) (totalizing n = 36)
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inhibitory effect against all isolates, but even better over 
Gram-negative. Chitosan AgNPs showed identical effect 
against Gram-positive and Gram-negative, indepen-
dently of its mechanism of resistance. In agreement with 
the MIC results, the PVA AgNPs had the time kill curve 
with less inhibition for all isolates evaluated. The most 
significant reduction in the number of cfu in the shortest 
period of time was achieved with chitosan AgNPs against 
MRSA and K. pneumoniae harboring KPC.
The ISO Technical Committee on Nanotechnolo-
gies (TC 229) has recently published two new standards 
methods for analysis of antimicrobial effect [8] and toxic-
ity of AgNPs [9]. However, a variety of other methodolo-
gies has been used in literature, as described by Jena et al. 
using colony-forming unit assay [27], Shrivastava et  al. 
used methods of agar dilution [28] and Patil et  al. used 
qualitative method of agar well diffusion to evaluate MIC 
of AgNPs [29]. This wide variety of methods makes the 
comparison of results a difficult task.
In the present study, diffusion in solid media, MIC, 
MBC, and time-kill methods were evaluated using cul-
ture media with and without blood. In all tests some 
degree of interference of the blood on enriched media 
was detected, with a reduction of all silver (AgNPs, silver 
sulfadiazine, and silver nitrate) activity against the micro-
organisms tested. In the presence of blood, we observed 
smaller inhibition zones, higher MIC and MBC, and a 
reduction on the inhibitory effect of death curve with 
reduction. Thus, media supplement with blood should be 
avoided to evaluate in vitro activity of AgNPs.
The diffusion method in depth by AWD was previ-
ously used as screening test to detect in vitro activity of 
AgNPs against bacteria [11, 13]. It is an easy method to 
be use in routine microbiology laboratory. The inhibi-
tion zones obtained in the present study showed similar 
AgNPs activity against MDR and susceptible isolates and 
that citrate and chitosan AgNPs presented greater effect 
against the isolates similar with the results using micro 
dilution method. The MIC90 results reinforced and vali-
dated the diffusion method results. This results can be 
explained by the fact that AgNPs interaction with three 
vital components of cells: peptidoglycan cell wall, cyto-
plasmic membrane and biomolecules like ribosomal 
DNA and phosphorus and sulfur groups present in pro-
teins [7, 30].
AgNP shows greater capacity and higher surface area-
to-volume ratio compared to silver salts [5, 30–32]. It is 
an aggregate of silver atoms up to 100  nm in diameter 
and its features change compared to both the ion and 
the bulk material in their chemical, mechanical, electri-
cal, optical properties, catalytic activity, conductivity and 
biological effect. Silver is the more effective antimicro-
bial agent against bacteria, viruses and other eukaryotic 
microorganisms [6, 33] than other metals such as copper, 
titanium, magnesium, zinc or gold.
The impact of the nanosize on silver activity against 
bacteria was already well demonstrated, Morones et  al. 
Fig. 7 Results of minimum bactericidal concentration/minimum inhibitory concentration (MBC/MIC) ratio of AgNPs particles (citrate, chitosan and 
PVA) and controls against multidrug-resistant (MDR) (n = 54) and susceptible (n = 36) bacteria
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Fig. 8 Comparison of time-kill curves for one oxacillin-resistant S. aureus (MRSA) and one oxacillin-suscpetible S. aureus (MSSA) isolate, using AgNPs 
particles (citrate, chitosan and PVA) and controls (silver sulfadiazine, silver nitrate and commercial AgNPs). For MRSA was made the comparison 
using MHB II broth and MHB II blood 1.25 %. MHB II- Mueller–Hinton Broth cation adjusted and microorganism; MHB II CTL-control without 
microorganisms. MHB II SGE-microorganism and broth enriched with blood; MHB II CTL SGE-only broth and blood. For oxacilin-susceptible S. 
aureus (MSSA3), silver sulfadiazine and silver nitrate curves were not done due to high MICs (Ag Sulfad and Ag Nitrate: MIC ≥27 μg mL−1; MBC 
≥27 μg mL−1)
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showed by a mapping analysis using the X-ray energy dis-
persive spectrometer (EDS) the effect of AgNPs and pure 
ionic silver against E. coli isolates [4]. The silver AgNPs 
were well distributed through the isolate electrostati-
cally adhered over the cellular membrane and inside the 
cytoplasm with consequent high inhibition. On the other 
hand, silver nitrate was noticeably less detectable over 
the isolate. Our results showed that AgNPs with PVA, 
a synthetic bio-friendly water-soluble polymer, had the 
lowest activity in all tests. Probably because of the higher 
Fig. 9 Comparison of time-kill curves for a carbapenem-resistant K. pneumoniae (KPC) isolate and an isolate of carbapenem-susceptible E. 
aerogenes, using AgNPs particles (citrate, chitosan and PVA) and controls (silver sulfadiazine and silver nitrate). MHB II- Mueller Hinton Broth cation 
adjusted and microorganism; MHB II CTL- control without microorganisms. For commercial AgNPs control the curve was not done due to high MICs 
(MIC ≥ 10 μg mL−1; MBC ≥ 10 μg mL−1)
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stability of the system PVA AgNPs as demonstrated by 
XRD (Fig. 3) and/or interaction with the –OH groups of 
PVA [34].
No impurities were detected in the XRD profile for 
AgNPs-PVA. However, some others peaks at 2θ angles 
of 32.2°, 46.3°, 54.7° and 57.3° were observed in the XRD 
profile for AgNPs-chitosan, which have been attributed 
in literature to both crystalline organic phase and Ag2O 
residues. Moreover, the spectrum of AgNPs-citrate 
shows no peak associate to metallic silver, which sug-
gests that the metallic silver were oxidized to ions during 
the drying process. Together, these results provide evi-
dence that the excellent in vitro inhibitory effect of citrate 
AgNPs and chitosan AgNPs against susceptible and MDR 
bacteria probably arises from the rapid oxidation process 
of these particles and release of Ag+ ions and/or the high 
surface charge of the particles.
Several factors can have impact on the effect of AgNPs 
against microorganisms such as size, shape, stability and 
concentration of AgNPs [35]. Apparently the charge of 
AgNPs causes less interference over the effect. At bio-
logical pH values, the overall surface of the bacteria is 
negatively charged due to the dissociation of an excess 
number of carboxylic and other groups in the membrane 
[4]. Some studies reported that electrostatic attraction 
between negatively charged bacterial cells and positively 
charged AgNPs is essential for the activity of AgNPs [36]. 
However, our results for positive charged chitosan AgNP 
and negative citrate AgNP were equivalent. Sondi and 
Salopek-sondi showed that negatively charged AgNPs 
present excellent antibacterial activity against gram 
negative E. coli. [37]. According to the authors, negative 
AgNPs somehow interact with the bacterial membrane, 
causing structural changes and degradation [37]. Fur-
thermore, several studies have demonstrated that the 
antibacterial activity of chitosan can result in a synergic 
effect in the Chitosan-AgNPs system [38, 39].
Regardless of the AgNPs charge, the growth inhibi-
tion of bacteria is related to the formation of Ag+ from 
the surface of the nanoparticles, attacking the mem-
brane lipids and leading to a breakdown of membrane 
function [40]. In this way, the antibacterial activities of 
AgNPs are critically dependent on surface oxidation and 
optimal particle dispersion [41]. Kim et al. demonstrated 
that the antioxidant N-acetyl cysteine (NAC) could influ-
ence antimicrobial activity induced by a slightly negative 
charged AgNP (surface zeta potential of −0.33 mV) [42]. 
The inhibitory effect was abolished by the addition of 
NAC, while NAC alone did not affect the antimicrobial 
activity. This can be explained by the fact that the nano-
size allowed expansion of the contact surface of Ag+ with 
the microorganisms despite the negative AgNP charge 
[42].
Studies had demonstrated the in  vitro activity of 
AgNPs against Gram-negative and Gram-positive iso-
lates, however the AgNPs activity against Gram-negative 
is not fully understood [4, 37]. The AgNPs effect against 
Gram-negative could differ based on the in vitro method 
used, and few studies used the gold standard method by 
muramic acid release and quantification by a gas chro-
matography-mass spectrometry (GC–MS) [8, 10]. Dawy 
et al. described better AgNPs inhibitory effect against S. 
aureus than E. coli and P. aeruginosa using agar diffu-
sion method, arguing that the lipopolysaccharide (LPS) 
could have a protective effect in Gram-negative bacte-
ria [40]. On the other hand, Shrivastava et al. evaluated 
by agar dilution and growth curve methods two strains 
of antimicrobial-susceptible microorganisms: S. aureus 
(ATCC 25923) and E. coli (ATCC 25922); and two anti-
microbial resistant: E. coli and S. typhus, and showed bet-
ter activity of AgNPs against Gram-negative [28]. Sondi 
and Salopek-Sondi studied one prototype of E. coli by 
agar dilution and growth curve and defended that Gram-
negative bacteria are more susceptible to AgNPs because 
the positive charges of Ag+ interact with the LPS of the 
cell membrane with greater affinity when compared to 
Gram-positive, resulting in the cell membrane pores [37]. 
Few studies used MIC and or MBC to evaluate the effect 
of AgNPs against bacteria [11, 43]. Egger et  al. evalu-
ated the effect of silica AgNPs and silver nitrate against a 
small number of Gram-negative (n = 5) and Gram-pos-
itive (n =  4) bacteria [43]. The MIC and MBC of these 
two groups differed significantly with greater suscepti-
bility against Gram-negative. The authors speculating 
that this effect can be due to the peculiarities of the cell 
wall of bacteria, Gram-positive contain multiple layers of 
peptidoglycan (around 30  nm) compared with the wall 
of Gram-negative bacteria (around 3 nm). Another pos-
sibility is the high content of teichoic and lipoteichoic 
acids common in Gram-positive that have strong nega-
tive charge that may hijack free Ag+ ions. Our MIC50 
results against MDR P. aeruginosa were 3.37, 6.75 and 
13.5 μg/ml respectively for Citrate AgNPs, chitosan and 
PVA lower than previously reported. Singh et  al. using 
“green synthesized” AgNPs by Phyllanthus amarus 
described MIC50 of 6.25 μg/ml [11] and using Tinospora 
cordifoliapara MIC50 of 50  μg/ml against P. aeruginosa 
[44]. Ansari et al. studied the action of AgNPs against S. 
aureus and reported MIC90 for MSSA of 25 μg/ml and 
MRSA of 50 μg/ml [5]. These findings were higher than 
our results that showed MIC90 for MSSA/MRSA 13.5 and 
6.75 μg/ml respectively for Citrate and chitosan AgNPs. 
Thus, this issue is still controversy and more studies are 
need.
Our results showed the great potential of silver AgNPs 
for clinical use. However, its toxicity and the concern 
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with the risk to the environment, with the growing accu-
mulation of these substances when disposed should be 
addressed.
Conclusions
The synthesized AgNPs, especially citrate and chitosan 
AgNPs, showed excellent in vitro inhibitory effect against 
susceptible and MDR bacteria. The AgNPs effect was 
superior against Gram-negative compared to Gram-posi-
tive. The inhibitory effect (MIC) was similar against MDR 
and susceptible bacteria, whit bactericidal (MBC) effect 
higher against susceptible isolates. It seems that media 
supplement with blood should be avoided to evaluate 
in vitro activity of AgNPs. Diffusion method in depth can 
be used as screening test, and MBC/MIC and time kill as 
reference methods.
The bactericidal effect of AgNPs can be translated into 
important therapeutic and clinical options in the future, 
especially considering the shortage of new antimicrobials 
against the emerging antimicrobial resistant microorgan-
isms, in particular against Gram-negative bacteria.
Methods
The study was performed in the Laboratory of Medi-
cal Research 54 (LIM-54) of the Faculty of Medicine 
of the University of São Paulo (FM-USP) and the Insti-
tute of research and development of Laboratório Fleury 
Medicina e Saúde.
Microorganisms
Silver compounds were studied against a set of 90 clini-
cal microorganisms, including MDR (n  =  54) and sus-
ceptible microorganisms (n = 36). The MDR belonged to 
different clones, previously characterized by pulsed field 
gel electrophoresis (PFGE), and obtained from laboratory 
strain bank LIM-54. Susceptible strains from Laboratório 
Alerta (Universidade Federal de São Paulo, UNIFESP) 
were also included and The American Type Culture Col-
lection (ATCC) and the Instituto Nacional de Controle de 
Qualidade em Saúde (INCQS)were used as control. The 
following resistance genes had been previously studied 
in Gram-negative and Gram-positive bacteria: carbape-
nem and polymyxin B-resistant A. baumannii (harboring 
oxa-23 and oxa-143 genes) (n = 12), carbapenem and pol-
ymyxin B-susceptible A. baumannii (n = 5), carbapenem-
resistant P. aeruginosa (harboring SPM and VIM genes) 
(n  =  5), carbapenem-susceptible P. aeruginosa (n  =  8), 
carbapenem-resistant Enterobacteriaceae (harboring 
extending spectrum beta lactamase ESBL and KPC-2 
genes) (n  =  12), carbapenem-susceptible Enterobacte-
riaceae (n = 9) and sulfamethoxazole/trimethoprim- and 
levofloxacin-resistant S. maltophilia (harboring Sul-1 
and Sul-2genes) (n  =  2). Oxacillin-resistant S. aureus 
(methicillin resistant S. aureus MRSA-SCCmec I, II, III, 
IVa, IVb and IVc positives) (n = 5), oxacilin-susceptible 
S. aureus (n = 8), vancomycin-resistant Enterococcus spp. 
(harboring vanA gene) (n =  8), vancomycin-susceptible 
Enterococcus spp. (n = 6)
AgNPs
The AgNPs particles (whit citrate, PVA and chitosan) 
were produced in the Instituto de Física de São Carlos, 
Universidade de São Paulo (IFSC-USP). All AgNPs were 
produced from 1  mM of AgNO3 (Sigma-Aldrich, St. 
Louis, MO, USA), resulting in 108 μg mL−1 AgNPs.
The amount of capping agents (citrate, chitosan and 
PVA) used in each synthesis depended on the stabilizing 
agent and it was optimized in order to have the best sta-
bility. Since citrate, PVA and chitosan presents different 
molecular weight and functionalization mechanism, the 
capabilities of them to stabilize the silver nanoparticles 
are different and the ratios between silver and capping 
agent had to be optimized in each case.
It is worth emphasizing that the main idea of this study 
was to evaluate which system could present the best anti-
microbial activity in terms of surface charge, size, and 
stability. Since these capping agents are very studied in 
synthesis of silver nanoparticles and present significant 
differences, they were chosen for this comparative study.
Synthesis of PVA, chitosan and citrate AgNPs
PVA AgNPs
PVA AgNPs were synthesized based on modification of 
previous methods [45, 47, 48]. Briefly, 30 mL of a 4 g L−1 
solution of polyvinyl alcohol (PVA, Mw 89,000–98,000) 
(Sigma-Aldrich’s. Louis, MO, USA) were mixture to 
30 mL of 1 mM of AgNO3 (Sigma-Aldrich) at room tem-
perature and under magnetic stirring. After 10 min, 1 mL 
of a cold solution of 0.1 mol L−1 NaBH4 (Sigma-Aldrich, 
St. Louis, MO, USA) were added. The system has passed 
from transparent color to yellow, indicating the forma-
tion of the nanoparticles [47].
Chitosan AgNPs
A similar strategy was used to produce the chitosan 
AgNPs [49]. Briefly, 30  mL of a 1  g  L−1 chitosan solu-
tion (Medium molecular weight, Sigma-Aldrich, St. 
Louis, MO, USA) containing 1 % acetic acid were added 
to 30 mL of a 1 mM solution of AgNO3 (Sigma-Aldrich, 
St. Louis, MO, USA) at room temperature and under 
magnetic stirring, followed by adding 1  mL of 0.1  mol 
L−1 NaBH4 cold solution. The color of the system also 
changed from transparent to yellow.
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Citrate AgNPs
Citrate AgNPs were synthesized based on previous meth-
ods with modifications [46]. For this, 30  mL of 1  mM 
AgNO3 solution (Sigma-Aldrich) were heated to boiling 
in a round-bottom flask connected to a condenser. After 
reaching the boiling point, 13  mL of a sodium citrate 
(Sigma-Aldrich) solution of 1  % w/v were added under 
vigorous agitation. After a few minutes, the solution 
color changed from transparent to yellow and the heating 
system was switched off.
Characterization of AgNPs (PVA, chitosan and citrate)
The optical properties of the AgNPs were character-
ized by Ultraviolet–Visible spectroscopy (UV–VIS) 
(HITACHI, U-2900) using a 1  cm quartz cell. The size 
and morphology of the silver nanoparticles were analyzed 
by Field Emission Gun Scanning Electron Microscope–
FEG-SEM (Zeiss) at 2.0  kV. For this, diluted samples of 
PVA, chitosan and citrate stabilized AgNPs were depos-
ited in silicon substrates without any further coating or 
processing and dried at room temperature. The surface 
charge of the particles was evaluated in suspension by 
zeta potential measurements (Zetasizer Nano, ZS90). 
The crystal structure of silver nanoparticles stabilized by 
PVA, chitosan and citrate were studied with X-ray pow-
der diffraction (XRD) in a Rigaku diffractometer, with 
CuKa (1.5406  Å) radiation. For this, the particles were 
synthesized according to the described previously, cen-
trifuged to remove the excess of stabilizers and dried at 
room temperature.
Controls
Silver sulfadiazine (Sigma-Aldrich, St. Louis, MO, USA) 
and silver nitrate (Sigma-Aldrich, St. Louis, MO, USA) at 
initial concentration of 54 μg mL−1 were used as control.
The commercial Sigma-Aldrich AgNPs (St. Louis, MO, 
USA) at concentration of 20 μg mL−1 with 60 nm sized 
nanoparticles, stabilized by citrate was used as control.
Tests The aim of the selected methods was to study 
the antibacterial effect of AgNPs produced. Their inhibi-
tory and bacteriostatic/bactericide effect, as well as the 
dynamic of bacterial killing were evaluated using the fol-
lowing tests:
Growth inhibition by diffusion
The test was carried out according to the agar well dif-
fusion (AWD) method [12, 13] as a screening of AgNPs 
inhibitory effect. To evaluate possible interference of 
enriched culture medium the growth inhibition tests in 
depth were performed using Mueller–Hinton Agar—
MHA (Biomerieux, Marcy L’Etoile, France) and MHA 
with sheep blood 5 % (Difco, Sparks, MD, USA).
The holes made in agar with 5 mm diameter were asep-
tically filled with 50 μL of AgNPs and controls. The plates 
were then incubated at 36 ± 1 °C for 24 h and inhibition 
zones measured, in millimeters, under reflected light.
Determination of minimum inhibitory concentration (MIC)
The AgNPs inhibitory power against bacteria was evalu-
ated using MIC. The MIC determination was carried out 
with Mueller–Hinton Broth -MHB II and Trypticase Soy 
Broth—TSB, and both showed similar results. The impact 
of blood was evaluated using MHB II 1.25 % sheep blood. 
The results were affected by the presence of blood, thus 
MHBII was chosen to perform all the tests.
The samples were diluted in a serial logarithmic base 
2 (log2), in MHB cation adjusted (MHB II) (BBL, Sparks, 
MD, USA), plus microbial suspensions with 104  cfu in 
MHB II (Difco), resulting in a micro dilution panel from 
1:4 to 1:256, following the methodology of CLSI docu-
ment M07-A9 [14]. According to original concentration, 
after initial 1:4 dilution PVA, chitosan and citrate AgNPs 
started from 27 μg mL−1, the controls silver nitrate and 
silver sulfadiazine started from 13.5  μgmL−1and com-
mercial AgNPs from 5 μg mL−1.The 96 micro well plates 
were incubated under 35 ± 1  °Cfor 16 to 18 h and read 
visually with transmitted light observing the presence 
or absence of turbidity. The first well with no microbial 
growth was defined as the MIC, expressed in μg  mL−1. 
To evaluate the reproducibility of the method, some tests 
were carried out in triplicate for sampling.
Minimum bactericidal concentration determination (MBC)
The concentration of AgNPs required to achieve the bac-
tericidal effect was defined using MBC. After reading the 
MIC, all wells without visible turbidity were plated in 
MHA and incubated under 35 ±  1  °C for 16–18 h. The 
plates were read visually with reflected light, observing 
the presence or absence of macroscopic bacterial growth. 
The lower dilution without macroscopic bacterial growth 
was defined as MBC. According to CLSI method for anti-
microbial drugs, described in the document M7-A9 [14].
The MBC/MIC ratio was used to define the mode of 
activity of silver derivatives: bactericidal when scores are 
1, 2 and 4 or bacteriostatic if score >4 [26].
Time‑kill tests
The dynamic of the AgNPs inhibitory effect was carried 
out using the time-kill curves under AgNPs concentra-
tion equal to 1 ×  MIC [50]. Four representative strains 
of MDR and antimicrobial susceptible Gram-positive 
and Gram-negative were evaluated by this method, one 
strain of S. aureus oxacilin-resistant and one oxacilin-
susceptible, K. pneumonia carbapenem-resistant and E. 
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aerogenes carbapenem-susceptible evaluated according 
with previous described [51, 52]. Shortly, after know the 
MIC for each AgNPs and microorganism evaluated were 
made tubes with 10 ml of MHBII and AgNPs at 1xMIC 
and 105 cfu/mL of each microorganism . For the negative 
control, AgNPs were substituted for MHBII. All tubes 
were incubated under 36 ± 1 °C and the number of viable 
microorganisms quantified on MHA at time 0, 3, 6, 12 
and 24 h. The number of viable cfu in each time was plot-
ted on a graph profiling the time-kill curve, compared to 
the curve of positive and negative controls.
The time-kill was not performed for the isolates 
with indeterminate MIC, that is, above the high-
est concentration tested (≥54  μg  mL−1, ≥27  μg  mL−1 
e  ≥  10  μg  mL−1). Except for MRSA isolate against the 
commercial AgNPs and MSSA isolate against PVA and 
commercial AgNPs. These were deliberately tested 
to show the shape of the curves in sub-inhibitory 
conditions.
To evaluate the blood interference observed in agar dif-
fusion and MIC, for the isolated S. aureus MRSA (M01) 
the curve was held in MHBII broth and MHBII 1.25  % 
sheep blood broth.
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